Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8253205 | 0.86 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL8256353 | 0.86 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL14450652 | 0.86 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL12050726 | 0.79 | L3MBTL1 (0.39) | PREP | |
| SCHEMBL12050751 | 0.79 | DPP4 (0.40) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL10208862 | 0.78 | DPP4 (0.51) | DPP4PREPDPP8DPP9 | |
| SCHEMBL8250544 | 0.74 | DPP4 (0.56) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL8253254 | 0.74 | DPP4 (0.56) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL8254460 | 0.71 | DPP4 (0.44) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL3362068 | 0.70 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | DPP4 1/4885PREP 14/4885DPP8 5/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885PREP 14/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.